The Journal of rheumatology · 2009
Limited utility of rapamycin in severe, refractory Wegener's granulomatosis.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Koening Curry L, Hernández-Rodríguez José, Molloy Eamonn S, Clark Tiffany M, Hoffman Gary S
Аннотация
OBJECTIVE: We report our experience using rapamycin in patients with Wegener's granulomatosis (WG) who failed to achieve remission with conventional treatment.
METHODS: Eight patients received rapamycin for severe, refractory WG. Clinical outcomes were reviewed retrospectively.
RESULTS: Four patients treated with rapamycin sustained remissions of at least 6 months' duration while receiving prednisone<or=10 mg/day; 2 relapsed during followup. Five patients discontinued rapamycin due to continued disease activity, cancer, or adverse events.
CONCLUSION: Toxicities due to rapamycin were numerous; consistent proof of efficacy in this pilot experience with WG was not seen.
METHODS: Eight patients received rapamycin for severe, refractory WG. Clinical outcomes were reviewed retrospectively.
RESULTS: Four patients treated with rapamycin sustained remissions of at least 6 months' duration while receiving prednisone<or=10 mg/day; 2 relapsed during followup. Five patients discontinued rapamycin due to continued disease activity, cancer, or adverse events.
CONCLUSION: Toxicities due to rapamycin were numerous; consistent proof of efficacy in this pilot experience with WG was not seen.